Cardlytics (CDLX) Q3 2026 Earnings Call Transcript

Cardlytics reported Q3 2026 billings of $57.2 million, down 32% year over year, and revenue of $32.9 million, down 30%, missing prior guidance amid advertiser budget pressure and a technical disruption at one U.K. bank partner. Adjusted EBITDA fell to $0.4 million from $3.3 million; the company ended the quarter with $29.9 million in cash and is evaluating options to improve its balance sheet and cash flow. Management forecast Q4 billings of $63 million–$69 million, implying 10%–20% sequential growth, and revenue of $35 million–$39 million, while expanding its rewards platform through new partners.

Analysis

The key issue is not just cyclical ad demand: CDLX has less qualified-user supply after bank-partner changes, while advertiser monetization per user has not yet demonstrated a durable recovery. Cost reductions are cushioning the decline, but near-breakeven EBITDA guidance leaves little room for another billing shortfall. The U.K. outage appears partner-specific; the broader exposure is reliance on third parties to deliver offers and access consumers, which CRP may diversify but also makes launch execution and economics critical.

The Q4 sequential rebound is a near-term catalyst, not proof of a turn. New CRP channels could expand reach and reduce bank concentration, but signed partners are not equivalent to active users, advertiser budgets, or profitable billings. The more informative evidence will be launch timing, incremental billings and contribution, repeat advertiser spend, and whether MQUs and ACPU stabilize. Management’s balance-sheet language also raises a potential dilution or financing overhang; verify facility terms, covenants, and cash runway in the 10-Q before underwriting recovery.

Contrarian angle: after a sharp operating decline, the low Q4 EBITDA range may limit expectations, while partner launches and seasonal spending offer upside. But investors may be overvaluing pipeline announcements relative to cash generation. Over 6–18 months, successful nonbank distribution could improve resilience; failure to convert it would leave a smaller, cost-cut structure exposed to bank-partner disruptions and advertiser budget shifts.

Key Decisions for Investors

• Avoid adding to a recovery position solely on Q4 sequential-growth guidance. Reassess after results against the $63–69 million billings range and evidence that contribution, not just billings, improves.
• Treat CDLX as a catalyst-driven watch rather than a high-conviction long until CRP launches show measurable incremental billings and repeat advertiser budgets. Verify launch cadence and cohort economics on subsequent calls.
• For existing exposure, keep position sizing conservative and monitor liquidity: review the 10-Q for credit-facility availability, covenants, cash burn, and any financing or dilution actions.
• A bearish position is more compelling only if Q4 billings miss guidance, adjusted EBITDA turns materially negative, or MQUs/ACPU continue deteriorating. A recovery thesis is weakened if new partner launches slip or fail to produce disclosed monetization.